https://gco.iarc.fr/today/online-analysis-multi
-bars?v=2018&mode=cancer&mode_popula
tion=countries&population=900&population
s=900&key=total&sex=0&cancer=39&type
=0&statistic=5&prevalence=0&population_
group=0&ages_group%5B%5D=0&ages_gr
oup%5B%5D=17&nb_items=10&group_ca
ncer=1&include_nmsc=1&include_nmsc_oth
er=1&type_multiple=%257B%2522inc%25
22%253Atrue%252C%2522mort%2522%2
53Atrue%252C%2522prev%2522%253Afa
lse%257D&orientation=horizontal&type_so
rt=1&type_nb_items=%257B%2522top%2
522%253Atrue%252C%2522bottom%2522
%253Afalse%257D&population_group_globo
can_id=

has been cited by the following article:

• TITLE: Incidence of Chemotherapy-Induced Amenorrhea in Premenopausal Patients with Breast Cancer Following Adjuvant Chemotherapy with Anthracycline and Taxane

  AUTHORS: Nguyen Tien Quang, Pham Tuan Anh, Le Van Quang, Nguyen Van Hai, Nguyen Duc Huan, Nguyen Cong Tin, Nguyen Thi Thanh Tam, Hoang Thu Hang, Nguyen Thi Thuy, Do Thi Thanh Mai, Tran Hoang Nam, Le Thi Hang

  KEYWORDS: Breast Cancer, Chemotherapy-Induced Amenorrhea, Adjuvant Anthracycline and Taxane-Based Chemotherapy

  JOURNAL NAME: Open Access Library Journal, Vol.7 No.1, January 8, 2020

  ABSTRACT: Breast cancer (BC) is the second incidence and the fifth leading cause to cancer death in the worldwide. In developing countries, the number of BC cases is still increased annually accompanied with the changes of lifestyle and screening programs. Nevertheless, the majority of BC patients are diagnosed as non-curative stage. Thereby, systemic therapy always plays an important role in BC treatment strategies. Among chemotherapy regimens, the combination of anthracyclin and taxane as an adjuvant treatment has been proven the efficacy and safety in terms of prolonging survival. In this study, we evaluated the incidence of chemotherapy-induced amenorrhea in breast cancer patients who were treated with adjuvant anthracycline and taxane-based chemotherapy.